Education
About Us
Working with TipRanks
Follow Us
Cormedix Inc. (CRMD)
:CRMD
Earnings Data
Report Date
Mar 31, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.82Last Year’s EPS
0.22Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted a transformative quarter for CorMedix, marked by record financial performance, strategic acquisitions, and promising future growth catalysts. Despite increased operating expenses and uncertainties surrounding DefenCath's post-TDAPA pricing, the company's strong revenue growth and strategic investments indicate a positive outlook.Company Guidance
Record Financial Performance
CorMedix reported the most successful financial quarter in its history, with record revenue of $104.3 million, net income of $108.6 million, and adjusted EBITDA of $71.8 million.
Acquisition of Melinta Therapeutics
CorMedix completed the acquisition of Melinta Therapeutics, leading to a diversified specialty pharmaceutical company with a broad portfolio and expected synergies of $30 million by the end of 2025.
Increased Revenue Guidance
Based on recent momentum, CorMedix raised its full-year revenue guidance from a minimum of $375 million to a range of $390 million to $410 million.
Strategic Investment in Talphera Inc.
CorMedix made a strategic minority investment in Talphera Inc., gaining a right-of-first negotiation to acquire the company following Phase III results.
Strong DefenCath Performance
DefenCath sales reached $88.8 million, with faster-than-expected adoption and utilization growth.
Future Growth Catalysts
Upcoming catalysts include the ReSPECT study for Rezzayo and DefenCath expansion into the prevention of CLABSI, targeting markets exceeding $2 billion and $750 million, respectively.
CRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $11.19 | $11.42 | +2.06% |
Aug 07, 2025 | $11.95 | $10.81 | -9.54% |
May 06, 2025 | $9.03 | $11.16 | +23.59% |
Mar 25, 2025 | $10.77 | $7.34 | -31.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cormedix Inc. (CRMD) report earnings?
Cormedix Inc. (CRMD) is schdueled to report earning on Mar 31, 2026, TBA (Confirmed).
What is Cormedix Inc. (CRMD) earnings time?
Cormedix Inc. (CRMD) earnings time is at Mar 31, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRMD EPS forecast?
CRMD EPS forecast for the fiscal quarter 2025 (Q4) is 0.82.